ANRIA
ALXN

American National Registered Investment Advisor’s Alexion Pharmaceuticals ALXN Stock Holding History

American National Registered Investment Advisor’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,860
Closed -$437K – 242
2021
Q1 		$437K Sell
2,860
-780
-21% -$121K 0.17% 178
2020
Q4 		$569K Hold
3,640
– – 0.23% 142
2020
Q3 		$417K Hold
3,640
– – 0.19% 144
2020
Q2 		$409K Hold
3,640
– – 0.2% 140
2020
Q1 		$327K Hold
3,640
– – 0.2% 143
2019
Q4 		$394K Hold
3,640
– – 0.19% 155
2019
Q3 		$357K Hold
3,640
– – 0.2% 152
2019
Q2 		$477K Hold
3,640
– – 0.27% 126
2019
Q1 		$492K Sell
3,640
-10
-0.3% -$1.24K 0.27% 124
2018
Q4 		$355K Hold
3,650
– – 0.22% 141
2018
Q3 		$507K Buy
3,650
+385
+12% +$48.3K 0.27% 127
2018
Q2 		$405K Hold
3,265
– – 0.19% 179
2018
Q1 		$364K Sell
3,265
-75
-2% -$8.96K 0.18% 192
2017
Q4 		$399K Buy
+3,340
New +$407K 0.19% 181

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

American National Registered Investment Advisor's ALXN Position: Q2 2021 in Review

American National Registered Investment Advisor sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 2,860 shares — an estimated $437K sold.

American National Registered Investment Advisor first reported a position in ALXN in Q4 2017 and held it in 14 quarters. The position peaked at $569K in Q4 2020. 710 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

  • American National Registered Investment Advisor reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • American National Registered Investment Advisor sold 2,860 Alexion Pharmaceuticals shares in Q2 2021, an estimated $437K.
  • American National Registered Investment Advisor first reported a position in Alexion Pharmaceuticals in Q4 2017 and held it in 14 quarters.
  • American National Registered Investment Advisor's Alexion Pharmaceuticals position peaked at $569K in Q4 2020.
  • 710 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on American National Registered Investment Advisor's 13F filing for Q2 2021, filed 10 Aug 2021.